CD274 and cancer: Thus, while increased PD-L1 expression on tumour cells can suppress the T cell response, it also makes cancer cells amenable to checkpoint blockade therapy with PD-1/PD-L1 inhibition promoting tumour cell susceptibility to T cell mediated killing [61,63].